Best Samad Podcasts (2025)

1
An AI supercomputer and discovering next-gen brain disorder treatments, with Tarek Samad 17:00

Play Pause

2d ago17:00

17:00

Gefion is Denmark’s first AI supercomputer, named after a goddess in Danish mythology. It is operated by the Danish Centre for AI Innovation (DCAI), a company established with funding from the Novo Nordisk Foundation, the world’s wealthiest charitable foundation, as well as the Export and Investment Fund of Denmark. In a new pharmaphorum podcast, w…

1
On genomics, NGS, and doing much more good than bad, with Markus Vossman 19:15

3d ago19:15

19:15

Illumina innovative sequencing and array technologies are fuelling groundbreaking advancements in life sciences research, translational and consumer genomics, and molecular diagnostics. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Markus Vossman, Germany general manager at Illumina, about innovative genomic applications and …

1
Delivering the right behavioural ingredients for the moment, with Amy Bucher 17:48

6d ago17:48

17:48

The FDA recently announced that it will begin offering faster drug reviews to certain medicines, reducing the drug review process from approximately ten months to one or two months. This news follows a series of rapid changes from the FDA since the Trump administration took office. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks wit…

1
AI for the planet, AI for life sciences – with Patrick Leung 13:16

7d ago13:16

13:16

In a new pharmaphorum podcast, guest Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials. The conversation touches upon how large language models (or LLMs) can be gotten into production in regulated spaces – and why generic models won’t cut it in this domain – as well as the role of real-world da…

1
On the future of AI in life sciences, with women at the helm 43:33

8d ago43:33

43:33

The Women in AI Healthcare event series - hosted by Real Chemistry in collaboration with Pharma Brands – brings together dynamic female leaders to discuss the transformative role of artificial intelligence in life sciences. It is also a call to action: to ensure women are not only present, but pivotal in shaping the future of AI in healthcare. In a…

1
On AI and computational support of biochemistry, with Alan Roth 21:24

9d ago21:24

21:24

AI’s growing influence in pharma is transforming traditional drug discovery timelines. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Alan Roth, CEO of Oxford Drug Design, about the use of AI to accelerate discovery of new treatments for cancer, infectious diseases, and cystic fibrosis. Roth discusses combining deep enzyme …

1
Harnessing the cell's own degradation machinery, with Benedict Cross 23:58

11d ago23:58

23:58

AI and computational small molecule drug discovery approaches are helping to realise the potential of targeted protein degradation (TPD) in molecular glue development. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Benedict Cross, Chief Technology Officer at PhoreMost, a company that’s specialises in next-gen TPD and which is …

1
How blood tests can inform cancer treatment decisions, with Craig Eagle 15:58

13d ago15:58

15:58

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer prognosis and treatment prediction. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Craig Eagle, Chief Medical Officer of Guardant Health, a precision medicine company that offers blood tests to inform cancer …

1
The NHS, system burden, and a transformation prescription, with Ruth Chambers 15:58

14d ago15:58

15:58

There is a world of difference between the NHS from its beginnings in 1948 and the NHS as it is now. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ruth Chambers OBE, co-director of Raparu Consult CIC and a visiting professor at Staffordshire University, for a conversation on her book, “Our NHS for better or worse?”. Chambe…

1
On CB1s as an alternative to GLP-1s, with Punit Dhillon 17:23

15d ago17:23

17:23

CB1 inhibition is an approach that taps into the body’s natural metabolism to burn fat while preserving muscle for more sustainable weight loss. Unlike GLP-1s, which suppress appetite, CB1 inhibition activates fat-burning processes. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Punit Dhillon, CEO of Skye Bioscience, for a conv…

1
Digital transformation as a third lever in the affordability debate, with Alfred Olivares 20:59

16d ago20:59

20:59

Technology and AI can help healthcare systems tackle the affordability challenge while ensuring patients still benefit from cutting-edge treatments. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Alfred Olivares, global managing partner, healthcare & medtech, at HTEC, in a conversation addressing how innovation can reach patie…

1
Towards a democratic era of medicine, with Simon Kohl 19:20

17d ago19:20

19:20

There are many efforts at the moment to transform the expensive, labour intensive, and high failure rate processes of drug discovery into automated drug design. And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl discusses Latent Labs’ emergence from stealth, as well as protein d…

1
CDMOs: Their crucial role and how to select one, with Sigma Mostafa 9:31

20d ago9:31

9:31

A CDMO plays a crucial role in the pharmaceutical and biotechnology industries by providing comprehensive drug development and manufacturing services, enabling companies to efficiently bring new medicines to market. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sigma Mostafa, CSO at KBI BioPharma, about the role of CDMOs and …

1
On US drug shortages and compounding pharmacies, with Shawn Hodges 12:36

21d ago12:36

12:36

Drug shortages are a critical issue in the US, leaving patients and healthcare providers struggling. Compounding pharmacies, however, can curb drug shortages and help lessen this growing threat to the public's health. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Shawn Hodges, CEO of Revelation Pharma, a nationwide network of…

1
Delving into the physics of cancer, with Lew Bender 26:30

22d ago26:30

26:30

Intra-tumourally injected therapeutics represent a novel approach to cancer cell death, with high tumour dispersion and cell penetration properties. To discuss the potential of these therapeutics to kill tumours and elicit an adaptive immune response within mere days of injection, pharmaphorum spoke with Lew Bender, CEO of Intensity Therapeutics In…

1
On inflammation, heart health, and GLP-1 possibilities, with Sandeep Kulkarni 22:48

24d ago22:48

22:48

There is a growing body of evidence on the role of inflammation in predicting heart health. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Sandeep Kulkarni, CEO of Tourmaline Bio, about addressing inflammation, and also the impact of AI and GLP-1s on cardiology clinical trials and drug development. Kulkarni also discusses Tourm…

1
On digital twins in rare disease research, with Piet van der Graaf 15:44

27d ago15:44

15:44

With over 7,000 rare diseases affecting an estimated 30 million people in the US alone, these conditions have long been underfunded and under-researched, leaving patients with limited options. However, virtual trials are emerging as a breakthrough. In a new pharmaphorum podcast, web editor Nicole Raleigh is joined by Piet van der Graaf, Senior VP a…

1
The hot topics of digitisation, with Rob Verheul 19:38

1M ago19:38

19:38

Graphite Digital’s study of 100 senior pharma leaders across Europe and North America earlier this year investigated organisations’ attitudes towards hot industry topics, including – of course – AI, omnichannel, and globalisation. So it was pharmaphorum web editor Nicole Raleigh welcomed Graphite Digital’s CEO, Rob Verheul, to the podcast as guest,…

1
Ten years of innovation at Frontiers Health – Live from Berlin with Jessica DaMassa 28:59

1M ago28:59

28:59

Last week in Berlin the Frontiers Health Conference celebrated its 10th Anniversary with a whirlwind two days of panels and presentations from founders, executives, and patients across the healthcare ecosystem. Whilst there, pharmaphorum editor-in-chief Jonah Comstock and web editor Nicole Raleigh, together with Frontiers Health co-host Jessica DaM…

1
Working together to innovate on pragmatic clinical trials, with Rob DiCicco 29:20

1M ago29:20

29:20

Process innovation in the pharmaceutical industry is never easy, but its best chance of success comes when companies come together to work on big problems – especially when they bring in regulators and other stakeholders. In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio managem…

1
Policy in Focus: Trump’s MFN deals, FDA vouchers, and the government shutdown 29:46

2M ago29:46

29:46

At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had reached a "deal" on most-favoured nations drug pricing. This was followed by similar announcements from AstraZeneca and Merck. But are these deals substantive policy or PR sleight of hand? In today’s e…

1
Biotech’s biggest challenge isn’t scientific, but political – with James Roosevelt Jr 11:54

2M ago11:54

11:54

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s political. In a new pharmaphorum podcast, James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy, and grandson of FDR, as well as Advisory Board Member for Pluri …

1
On targeted radiotherapeutics, with Marc Hedrick 34:30

2M ago34:30

34:30

Radiation has for over a century been considered one of the most powerful methods of destroying cancer. But, even now, ways to deliver significant doses to a tumour without damaging normal surrounding tissue are few. And this is where targeted radiotherapeutics come in. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Marc He…

1
Towards one, cohesive AI workflow: In conversation with Ilya Burkov 12:28

2M ago12:28

12:28

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences at Nebius, a company building one of the world’s leading AI infrastructure companies. Burkov discusses the deployment of AI and cloud-native infrastructure for improving the speed and indeed quality of drug development, as wel…

1
Collaborating on a connected platform journey, with Alexander Alex and Florian Schnappauf 29:19

2M ago29:19

29:19

Bayer and Veeva have partnered for several years across commercial, R&D, and quality functions. But recently Bayer migrated to Veeva’s Vault CRM, taking that relationship, and Bayer’s connected platform journey, to the next level. In order to discuss this migration further, pharmaphorum spoke with Alexander Alex, head of Veeva Platform at Bayer, an…

1
ESMO25: Patient-centric oncological futures with Boehringer Ingelheim 14:28

2M ago14:28

14:28

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a treatment for HER2-positive non-small cell lung cancer (NSCLC), tumour shrinkage observed by investigator review - Boehringer Ingelheim is racing to expand its label. As the company reported new data at the Congress from the phase 1b…

1
Smoothing a contract pathway through uncertainty: In conversation with Neal Masia 30:30

2M ago30:30

30:30

Back in June, pharmaphorum spoke with Entity Risk’s CEO and co-founder, Neal Masia, a leading health economist, about the unknowns unfolding in the US following the commencement of the second Trump administration this year. Tune into today’s podcast for an exploration of the potential scenarios Masia mused might arise, as well as his insights on th…

1
FH25: On the future of health, with Frontiers Health Chairman Roberto Ascione 12:44

2M ago12:44

12:44

In the final episode of our special Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with the Chairman of Frontiers Health, Robert Ascione. Ascione - a serial entrepreneur & thought leader in health innovation and digital health, global executive, CEO and founder of Healthware Group, and President of Hea…

1
Allosteric small molecule therapies in PD, with Gene Mack 20:01

3M ago20:01

20:01

As Gain Therapeutics announces positive Phase 1b results for its lead compound, GT-02287, pharmaphorum looks back to a conversation with the company’s CEO Gene Mack earlier in the year, discussing allosteric small molecule therapies in the Parkinson’s disease space. Mack discusses the company’s progress in this field, and explores where next in ter…

1
FH25: Jessica DaMassa on hosting, hype, and health innovation 29:41

3M ago29:41

29:41

As one of Frontiers Health’s most recognisable faces (and voices), Jessica DaMassa, founder of WTF Health and long-time emcee of the conference, has had a front-row seat to the events evolution over the last decade. In this episode of the pharmaphorum podcast’s special Frontiers Health anniversary series, DaMassa joins Deep Dive editor, Eloise McLe…

1
Improving ROI on AI investments and data quality, with Dr Jay Anders 17:12

3M ago17:12

17:12

Healthcare organisations are facing the simultaneous pressures of demonstrating ROI on AI investments, addressing clinician burnout, and satisfying compliance requirements. In a new pharmaphorum podcast, Dr Jay Anders, chief medical officer for Medicomp Systems, and also host of the Tell Me Where IT Hurts podcast, discusses why he believes that the…

1
The importance of being disruption ready, with Brandon Pence 19:36

3M ago19:36

19:36

The cell culture media industry is currently experiencing significant growth, driven by the increasing demand for biopharmaceuticals, advancements in tissue engineering, and the rising number of research activities in cell biology. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brandon Pence, who was recently appointed Preside…

1
FH25: Commercialising Health Tech and Deeptech, with Pilar Fernández Hermida 34:03

3M ago34:03

34:03

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida, founder of i-Expand, a commercial strategy firm focused on assisting Health Tech and Deeptech companies grow and monetise. Fernández Hermid…

1
Agentic AI, culture shifts, and commercialisation today: Anthony Cilento post-Axtria Ignite 2025 11:57

3M ago11:57

11:57

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Anthony Cilento, vice president, data science & customer insights, at Bayer, in a post-Axtria Ignite 2025 discussion on the conference and agentic AI more generally. Cilento speaks to the advancement from GenAI to agentic AI, what’s changed for his own team in this regard and what’…

1
FH25: On patient access and equity, with Roberta Sarno 19:28

3M ago19:28

19:28

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with founder, director, and global health advisor at D-Health Consulting, Roberta Sarno. Sarno is also director of the APAC Liver Disease Alliance, and consultant on digital health APAC policy at …

1
FH25: On healthcare innovation with Gary Monk 11:25

3M ago11:25

11:25

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with healthcare innovation consultant Gary Monk. Monk shares his favourite memory from the conference’s past decade, and discusses its ethos, as well as how his work at the moment aligns with that…

1
FH25: The art of connection at Frontiers Health with Aline Noizet 11:04

3M ago11:04

11:04

Frontiers Health marks its 10th anniversary this year, celebrating a decade of innovation, collaboration, and the connections that drive progress. In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Aline Noizet, founder of Digital Health Connector – a phrase that she says…

1
Policy in Focus: Trump’s Most Favoured Nations drug pricing scheme – with Alice Valder Curran 35:41

3M ago35:41

35:41

In Donald Trump's first presidential term, he spoke a lot about "Most Favoured Nations" pricing for pharmaceuticals - that is, bringing the prices that Americans pay for drugs in line with prices paid around the world. In his first term, all that talk didn't amount to much. But this time around the pharma industry is taking the President much more …

1
FH25: Exploring the intersection of patients, HCPs, and technology with Denise Silber 12:54

3M ago12:54

12:54

Frontiers Health is back, and celebrating 10 years of innovation, conversation, and collaboration. In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Denise Silber, founder of Basil Strategies and Doctors 2.0. Having spent more than two decades working at the intersection…

1
Doing good in people’s lives: Amy Burroughs discusses CML 10:39

4M ago10:39

10:39

Chronic myeloid leukaemia (CML) is a unique disorder in the rare disease sector because there are multiple approved therapies for patients and, in the US alone, the prevalence of CML is expected to triple by 2040. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Amy Burroughs, CEO of Terns Pharmaceuticals, about available treatm…

1
FH25: Individual centric investing with Steve Seuntjens 9:12

4M ago9:12

9:12

In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital. Seuntjens has long been focused on investing in innovation that puts the individual at the centre of health. For him, building companies is never easy – but it becomes meaningful w…

1
Pharma and health advertising: Brian Coane on the necessity of humour 17:17

4M ago17:17

17:17

When it comes to breaking down barriers, humour is vitally important, helping to do away with stigma when it comes – in particular – to pharma and health advertising. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brian Coane, health partner at creative agency Leith, who talks sensitivity, maximum impact, and overcoming the fe…

1
The glimmer of opportunity behind the storm: Ali Pashazadeh talks biotech investment 26:11

4M ago26:11

26:11

Biotech finance has encountered what can arguably be termed the worst perfect storm in its history, and private investment in biopharma is in the midst of the longest drought. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, a strategic and financial advisory …

1
FH25: The intersection of tech, science & design with Unity Stoakes 10:11

4M ago10:11

10:11

This year marks the 10th anniversary of Frontiers Health. In this episode of our Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Unity Stoakes, president and co-founder of Startup Health and Advisory Board Member at The NeuroTech Collider Lab, University of California, Berkeley. Stoakes has spent 3…

1
Changing the drug development treatment paradigm: Hilary Eaton on AI and LLMs 23:33

4M ago23:33

23:33

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Hilary Eaton, a rare disease advocate and chief business officer at Profluent about AI-first protein design and its part in accelerating biomedicine. Eaton discusses her advocacy, gene editing, and how real-world evidence shows that AI scaling laws – which predict model performanc…

1
Increasing trial efficiency: Adityo Prakash talks small datasets, real-world scenarios, and organoids 17:01

4M ago17:01

17:01

Characterising the behaviour of drugs in humans has historically required extensive clinical trials at considerable time and cost. So, any lab-derived early insight into how drugs will behave in human patients can make drug trials vastly more efficient. In this episode, the pharmaphorum podcast welcomes Adityo Prakash, founder and CEO of Verseon, a…

1
FH25: Ten years at the forefront of health innovation, with Kristin Milburn 13:00

4M ago13:00

13:00

This November marks a major milestone for health innovation as Frontiers Health celebrates its 10th anniversary. To mark the occasion, pharmaphorum is proud to launch a special limited-edition podcast series, bringing you conversations with the people who’ve helped define the conference over the years – and those driving the next wave of innovation…

1
MAPs, EAPs, and patient access: Suzanne Aitken on the challenges for pharma 15:57

4M ago15:57

15:57

Managed Access Programs (or MAPs) enable mechanisms for patients with unmet medical needs to get access to new medications outside of the clinical trial setting and well before marketing authorisation and reimbursement in a patient's country. Also referred to as Expanded Access Programs and Early Access Programs, these programs are not limited to t…

1
Weighing in on GLP-1 drugs 35:42

4M ago35:42

35:42

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the drugs and where it could go next to the cultural and societal implications of this highly effective treatment for diabetes, weight loss, and potentially much more. On today’s podcast editor-in-chief Jonah Comstock and Deep Dive e…

1
The TechBio way: Brendan Frey talks genomics, AI, and RNA 26:34

4M ago26:34

26:34

Overall, the pharmaceutical industry is moving away from an approach where AI is task-driven, narrowly focused on a single, isolated problem. Instead, companies are embracing foundation models which, trained on very large and broad datasets, are versatile, and capable of tackling a range of complex challenges simultaneously. In a new pharmaphorum p…